Neurocrine Biosciences, Inc. (FRA:NB3)

Market Cap	11.64B
Revenue (ttm)	2.29B
Net Income (ttm)	364.78M
Shares Out	n/a
EPS (ttm)	3.57
PE Ratio	31.91
Forward PE	14.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	41
Open	115.20
Previous Close	118.70
Day's Range	115.20 - 115.20
52-Week Range	77.78 - 147.45
Beta	n/a
RSI	36.91
Earnings Date	Feb 9, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NB3

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD